Federal Grants

The purpose of the Childrens Hospitals Graduate Medical Education (CHGME) Payment Program is to compensate for the disparity in the level of federal graduate medical education (GME) funding for freestanding childrens teaching hospitals versus other types of teaching hospitals. Federal funding for GME is primarily provided by the Centers for Medicare and Medicaid Services (CMS) and goes to full-service teaching hospitals that serve primarily adult patients. Freestanding childrens hospitals receive little to no GME funding from Medicare because childrens hospitals have a low Medicare caseload. The CHGME Payment Program is administered by the Bureau of Health Workforce (BHW), Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services (HHS).

Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Revised Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on December 7, 2022. Purpose of Program: The purpose of the SCTAC grant program is to advance the mental health and well-being of early learners (as defined in this notice), school-age children and youth, and educators and other school staff, by making grants to State educational agencies (SEAs) to provide technical assistance and capacity building to high-need local educational agencies (LEAs) (as defined in this notice). Assistance Listing Number (ALN) 84.424H.

PROGRAM DESCRIPTIONThe U.S. Consulate General in Erbil of the U.S. Department of State announces an open competition for organizations to submit applications to carry out a program to build capacity among social media influencers, journalists, and journalism students in the Iraqi Kurdistan Region (IKR) and Kirkuk governorate. Please follow all instructions below.Priority Region: Iraqi Kurdistan Region. Priority will be given to projects which include audiences from outside the three major cities of Erbil, Duhok and Sulaimani. Program Objectives: The rise of AI-generated disinformation poses significant concerns to the ability of the public and media to fairly and accurately report on current events, given the ability of bots to spread information, and deepfakes to make it extraordinarily difficult to tell truth from fiction putting democracy itself at risk. This program will train 15 social media influencers and 100 newly minted journalists (fewer than 5 years of service) or journalism students on how AI is used to produce and disseminate disinformation, how to recognize disinformation, and how to explain this in clear language to their audiences without scare tactics, in a way that empowers audiences rather than demoralizes them. Influencers should, as a result, create at least two pieces of unique content on disinformation for their audiences; journalists and journalism students should write and publish at least two stories on disinformation. Participants and Audiences:This program envisions two separate trainings: one focused on 15 significant social media influencers (minimum numbers of followers to be determined), and one for 100 journalism students or journalists with fewer than 5 years of service.

The "Privacy-Preserving Data Sharing in Practice" grant aims to fund research and development projects that create practical, scalable technologies for sharing data in a way that preserves privacy, with a focus on advancing privacy-enhancing technologies for artificial intelligence, developing tools and testbeds for safe data sharing, and promoting the usability and inclusiveness of these solutions.

The Academy of Kidney Cancer Investigators (AKCI) is a unique, interactive virtual academy that provides, intensive mentoring, national networking, and a peer group for scientist and clinician junior faculty. The KCRP created the Academy of Kidney Cancer Investigators in FY19 to align with several program priorities, which include to build research capacity in kidney cancer; increase collaborations to advance kidney cancer research, and support innovative research conducted by the next generation of kidney cancer scientists and clinicians. The overarching goal of the AKCI is to increase research capacity in kidney cancer through the development of successful, highly productive kidney cancer researchers in a collaborative research and training environment. The AKCI is a virtual career development and research training platform that currently consists of 11 Early-Career Scholars (ECS)/Designated Mentor pairs from different institutions, and one Academy Director. It is expected that six Early-Career Scholars will graduate by the fall of 2025 and four FY23 AKCI Early-Career Scholars/Designated Mentor awards will be made by September 2024. In addition, Academy graduates will continue to participate in the annual Academy meetings. Information about the Academy is available on the KCRP webpage and in the Kidney Cancer Program Booklet at https://cdmrp.health.mil/kcrp. The AKCI leadership team will identify opportunities for engagement with KCRP AKCI Scholars-Designated Mentors and KCRP FY25 (and subsequent year awardees) Postdoctoral and Clinical Fellowship Awardees. The Academy Director and Deputy Director catalyze the growth and professional development of the Early-Career Scholars in collaboration with their Designated Mentors, assess the progress of the ECSs, and facilitate communication and collaboration among all of the Academy members. The AKCI leadership team will also identify and offer opportunities for engagement (e.g., invitations to seminar series and in-person meetings) with FY24 Postdoctoral and Clinical Fellowship Awardees with FY24 KCRP AKCI-ECS-Designated Mentors (and subsequent year awardees). This FY24 funding opportunity is soliciting applications for an Academy Director (Principal Investigator [PI]) and Deputy Director (Partnering PI) to lead the AKCI. The newly selected FY24 Academy Director and Deputy Director will initiate their responsibilities no later than October 2025. The Academy Director and Deputy Director (hereafter referred to as Academy Leadership) must be established kidney cancer researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early career investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars with their Designated Mentors in the AKCI. Other objectives will include execution of research that will engage AKCI FY24 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in kidney and renal pelvis cancers. The leadership team will identify and offer occasion(s) for the AKCI to network with KCRP FY24 Postdoctoral and Clinical Fellowship Awardees (and subsequent year awardees). Designated Mentors on FY24 KCRP AKCI Early-Career Scholar Award applications and Designated Mentors on open FY19 through FY23 KCRP AKCI Early-Career Scholar Awards (with the exception of those graduating in 2024) are not eligible to apply for this award. Note: An invited oral presentation is a requirement for application review of the KCRP AKCI LA, as described in Section II.D.2.b.iv, Additional Application Components. Responsibilities of the Academy Leadership include, but are not limited to: Act as a resource for all Scholars and Designated Mentors in the Academy over the Scholars 4-year period of performance. Facilitate communication and collaboration among all Scholars and Designated Mentors (including periodic interactive communication among all Academy members). Develop assessment criteria to evaluate the research progress made by all Scholars, as well as their career progression and sustainment as independent investigators in kidney cancer research. Conduct collaborative kidney cancer pilot project(s) that include Academy Scholars. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact kidney cancer research and/or kidney cancer patients/survivors. o Examples of pilot research projects may include but are not limited to (a) funding an extended statistical or bioinformatics analysis with AKCI Scholars, (b) performing a large-scale meta-analysis of human or animal datasets with AKCI scholars, (c) provide access to critical biorepositories or animal models to expand AKCI investigator analyses or increase study rigor. Provide constructive critiques with the goal of advancing the research and professional careers of the Scholars and strengthening the mentorship of the Designated Mentors. Provide avenues to increase the promotion of the Academy and visibility of Scholars within kidney cancer research and advocacy communities (e.g., peer review, conferences, editorial boards). Support the professional development, to include laboratory management skills, of the Scholars into leading researchers through invited presentations by experts outside of the AKCI LA. Plan and host an annual 1-day workshop and, biennially, a multi-day workshop for all Scholars/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the AKCI. Scholars will be responsible for their own travel costs to in-person Academy meetings. Include KCRP FY24 Postdoctoral and Clinical Fellowship Awardees in at least one meeting of the FY24 AKCI. These investigators will be responsible for their own travel costs, funds for which are included in their research awards. Establish a panel of patient advocates and Veteran(s) (i.e., the Patient Advocacy Panel) to inform the AKCI on the needs of the patient community. Establish the Designated Mentor Panel to facilitate collaborations among the AKCI participants including the Scholars, Academy Director/Deputy Director, and the Designated Mentors. The Academy of Kidney Cancer Investigators Leadership Award is structured to support two PIs. The Academy Director will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Deputy Director will be identified as the Partnering PI. The collaboration between the Academy Director and the Deputy Director should be supported by complementary expertise and experience. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to support the success of the Scholars. While it is up to the Academy Director and the Deputy Director to define their roles, both Academy Leaders should have interactions with each Scholar-Designated Mentor pair, (and the Scholars Designated Mentors); acting as administrative support does not fulfill the intent of the Director and Deputy Director. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be cooperative agreements (31 USC 6305). Substantial CDMRP programmatic involvement with recipients is anticipated during the performance of award activities. Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate, or participate in project activities including but not limited to: Participating in the Steering Committee that oversees study conduct. Make recommendations for continued funding based on (a) overall study progress, including sufficient patient and/or data accrual; (b) cooperation in carrying out the research (e.g., attendance at Steering Committee meetings, implementation of group decisions, compliance with the terms of award and reporting requirements); and/or (c) maintenance of a high quality of research. The anticipated combined direct costs budgeted for the entire period of performance for a FY24 KCRP AKCI LA should not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.4M to fund approximately one KCRP Academy of Kidney Cancer Investigator Leadership Award application (consisting of an Initiating PI application and a Partnering PI application). Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 and FY26 funds, which will expire for use on September 30, 2030, and September 30, 2032, respectively.

The FY24 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed and should not be discussed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Organizational-Level Emphasis Areas:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Guidelines, for more information.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Concept Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $1.44M to fund approximately nine Concept Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Office of the Public Affairs Advisor (PAA) at the U.S. Mission to NATO (USNATO) is pleased to announce that funding is available through its Public Diplomacy Small Grants Program. This is an Annual Program Statement, outlining our funding priorities, the strategic themes we focus on, and the procedures for submitting requests for funding. Please carefully follow all instructions below. Purpose of Small Grants: PAA invites proposals for programs and initiatives that help promote an increased understanding of NATOs role in promoting regional peace and security, as well as the rules-based international order. All programs must include a direct tie to the United States. This could be via American expert/s, organization/s, or institution/s in a specific field that will promote increased understanding of U.S. foreign policy interests within the Alliance. Examples of PAA Small Grants Program projects include, but are not limited to: Academic and professional lectures, seminars, and speaker programs Artistic and cultural workshops, performances, and exhibitions Professional and academic exchanges, programs, and trainings Digital engagements and content creation Establishing core leadership/influencer groups, such as a young leaders network Developing educational materials Priority Region: While activities targeting NATO Allies and partner countries will be prioritized, programs that support NATO objectives or increase understanding of NATO in other strategically important countries will also be considered. Priority Program Areas: USNATO PAA invites proposals for programs and initiatives on the following priority program areas: Countering disinformation and misinformation Media independence or media literacy NATO deterrence and defense, including its new military plans Hybrid security threats and emerging technologies Science and technology NATO and Africa, Asia, or Latin America NATO partnerships Russian malign influence in the Euro-Atlantic area The Peoples Republic of Chinas expanding use of economic, political, and military power Climate security Women, Peace, and Security Young professionals and next generation engagement We strongly encourage: New and creative approaches that utilize emerging technologies, innovative audience engagement, and targeted audience reach Programs that seek to reflect diversity of thought and backgrounds, gender balance, and focus on intersectionality Programs and initiatives that incorporate and empower emerging voices, such as youth audiences Product outputs with multiplying effects Product outputs in two or more languages Forthright analysis about the gaps in NATO strategies along with practical solutions to address deficiencies Implementation plans that incorporate evaluation components, such as key performance indicators (KPIs) to track a quantifiable measure of performance

The "Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH)" grant aims to support research that develops new behavioral measures and data infrastructure to improve the diagnosis, prognosis, and treatment of mental disorders.

The Early Investigator Research Award supports NF-focused research opportunities for individuals in the early stages of their careers, under the guidance of a Designated Mentor. This opportunity allows for early-stage investigators to develop a research project, investigate a problem or question in NF research, and further their intellectual development as an NF researcher of the future. The postdoctoral investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of NF research; however, the PI is not required to have previous NF research experience. Applications must include at least one mentor, appropriate to the proposed research project, who has experience in NF research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The Designated Mentor can be a junior faculty member, in which case the PI is encouraged to include a co-mentor with a more robust track record in NF research and mentorship. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as an NF researcher.

Under the authority of Section 21 of the Occupational Safety and Health Act of 1970 (OSH Act), the U.S. Department of Labor (DOL) Occupational Safety and Health Administration (OSHA) established its discretionary grant program in 1978. In 1997, OSHA renamed the program in honor of the late Susan Harwood, former director of the OSHA Office of Risk Assessment. The grant program offers opportunities for nonprofit organizations to compete annually for funding so they may develop and conduct training and educational programs for small business employers and workers.The Susan Harwood Training Grant Program aims to advance the job quality of the American workforce by providing disadvantaged, underserved, low-income, or other hard-to-reach, at-risk workers with hazard awareness, avoidance, and control training to protect them from on-the-job hazards, and to inform workers of their rights and employers of their responsibilities under the OSH Act.The program and this funding opportunity announcement prioritizes investment and funding to train workers and employers impacted by working in high-hazard industries, industries with high fatality rates, or whose workforce has historically had disadvantaged access to occupational safety and health training, including young workers, temporary, minority, low literacy, limited-English speaking, and other disadvantaged and hard-to-reach workers and worker communities. The Susan Harwood Training Grant Program seeks to increase access to life-saving training by encouraging grantees to provide the training in other languages. Technical assistance, guidance, and support for this funding opportunity is presented in OSHAs FY 2024 Susan Harwood Training Grant Funding Opportunity Overview available at: www.osha.gov/harwoodgrants/applicant-information.The program is designed to support and enable nonprofit organizations efforts to provide this important occupational safety and health training to disadvantaged workers. These nonprofit organizations include qualifying labor unions; community-based, faith-based, and grassroots organizations; employer associations; Native American tribes; tribal Alaska Native, Native Hawaiian, and native-controlled organizations that are not an agency of a state or local government; and public/state-controlled institutions of higher education. The program provides education and training on advancement of workers workplace rights and protections against discrimination and reprisal.The Susan Harwood Training Grant Program seeks applications that include proven strategies to reach the target training populations while also developing innovative solutions to expand access. Grantees agree to participate in the data collection and training impact evaluations described in this funding opportunity announcement.The Susan Harwood Grant Program awards funds to qualifying organizations who have demonstrated capabilities to achieve the programs performance expectations outlined in this FOA. This includes experience in engaging subject matter experts, delivering and administering adult training programs, recruiting students, and managing grants. Following the grant awards, OSHA monitors each organizations progress in achieving their performance goals and training targets. OSHA accomplishes this by conducting orientation meetings, training material reviews, training observations, program and financial monitoring visits, and quarterly and year-end report reviews. For FY 2024, OSHA announces the availability of $12,787,000 in funding for new Susan Harwood Training Program grants based on 2024 federal appropriations. OSHA expects to award multiple grants to eligible nonprofit organizations under this competitive FOA. This FOA does not itself obligate any federal funds. The obligation of funds occurs when grant recipients acknowledge receipt and acceptance of award documents. Program funding is for a 12-month period beginning no later than September 30, 2024, and ending on September 30, 2025. The maximum award for a Targeted Topic Training grant is $160,000.Applications submitted under this FOA are competing for a Targeted Topic Training grant. Targeted Topic Training grant applicants must propose to develop and conduct instructor-led training addressing one of the OSHA-specified training topics for an audience identified in this funding opportunity. Organizations are restricted to one Susan Harwood Targeted Topic Training grant, Training and Educational Materials Development grant, or Capacity Building grant award in a fiscal year. If an organization submits applications for multiple Susan Harwood funding opportunities, OSHA will review the last complete and viable application package submitted.

The NFRP Synergistic Idea Award supports new ideas that represent synergistic approaches to NF research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in NF research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.

The NFRP Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required.

Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Revised Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on December 7, 2022. Purpose of Program: The purposes of this program are to (1) help address State-identified needs for personnel preparation in special education, early intervention, related services, and regular education to work with children, including infants, toddlers, and youth with disabilities; and (2) ensure that those personnel have the necessary knowledge, skills, and competencies derived from practices that have been determined through scientifically based research, to be successful in serving those children. Assistance Listing Number (ALN) 84.325B.

The FY24 KCRP Postdoctoral and Clinical Fellowship Award supports recent doctoral or medical school graduates in pursuit of innovative, high-impact kidney cancer research during their postdoctoral and/or clinical fellowship and allows them to obtain the necessary experience for an independent career as a leader in kidney cancer research. Applicants must demonstrate that the proposed research has high potential to lead to, or make, significant advancements in kidney cancer research and/or patient care. Applicants for this award must also exhibit a strong desire to pursue a career in kidney cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in kidney cancer. The critical components of this award mechanism are: Impact: Research supported by the FY24 KCRP Postdoctoral and Clinical Fellowship Award will have the potential for a major impact and accelerate progress toward ending kidney cancer. The impact may be short term or long term, but must move beyond an incremental advance. Applications are expected to identify the kidney cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Strategy: The research proposed as part of the Postdoctoral and Clinical Fellowship Award must have high potential to lead to or make breakthroughs in kidney cancer. The scope of the research may include innovative, high-risk/high-reward research in the early stages of idea development or research already supported by preliminary data with the potential to make significant advancements toward clinical translation. The research strategy should demonstrate sound rationale, logical reasoning, and, if available, preliminary data. The proposed research should show evidence of rigorous experimental design, sufficient experimental details, appropriate controls, a statistical plan, and consideration of pitfalls and alternatives. Principal Investigator (PI): Under this award mechanism, the postdoctoral or clinical fellow is considered the PI and, as such, is expected to write the project narrative, researcher development plan, and other application components, with appropriate guidance from the mentor. While the PI is not required to have previous experience in kidney cancer research, the proposed project and researcher development plan must focus on kidney cancer. Applications must emphasize the PIs potential for success in becoming an independent kidney cancer researcher based on their qualifications, achievements/honors (including first-author publications and funding), and letters of recommendation. Mentor: The mentor (or co-mentor, if applicable) must possess the appropriate experience in kidney cancer research and/or patient care, to include recent publications and a record of active funding, and clearly demonstrate a commitment to guiding the PIs research and development as a researcher. If the mentor is not an experienced kidney cancer researcher, then formal co mentorship by an established kidney cancer researcher is required. The application must include information about the mentors experience in conducting innovative research and how they intend to support the PIs endeavors in kidney cancer. Mentorship by an investigator without an established record of mentoring pre- and/or postdoctoral trainees may be offset by the overall strength of the researcher development plan. Researcher Development Plan: Applications must provide details on the suitability of the PIs overall researcher development plan for attaining the goals of this award mechanism. Applications must elaborate on the qualities of the research environment in which the candidate will work, provide details on the individualized kidney cancer-focused researcher development plan, and describe how it will facilitate the PIs career development as an independent, innovative kidney cancer researcher. A multidisciplinary research approach to kidney cancer is highly encouraged, but not required; however, if there are multidisciplinary aspects, they should be clearly outlined in the application. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this program announcement. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Postdoctoral and Clinical Fellowship Award should not exceed $195,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.18M to fund approximately seven Postdoctoral and Clinical Fellowship Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

U.S. Embassy Mexico City of the U.S. Department of State announces an open competition for organizations to submit applications to carry out a program to promote workforce development in the printed circuit board (PCB) industry through curriculum development for PCB focused courses at secondary and tertiary educational levels, certificate programs, vocational instruction, dual education, technical English language skills building, and full or partial support for internships in Taiwanese PCB manufacturing firms either in Taiwan or Mexico.

This funding opportunity supports cultural organizations in creating public humanities programs that commemorate the 250th anniversary of the Declaration of Independence, focusing on historical significance and community engagement.

USAID is exploring the design of a new Monitoring, Evaluation, Collaboration, Learning and Adaptation (MECLA) activity to provide third party monitoring, evaluation, collaboration, learning, and program support services to strengthen the implementation of USAID/Afghanistans Strategic Framework and ensure development programs are on the right track to achieve their intended results. For details, please refer to the RFI document attached.

GCJ seeks to advance victim-survivor-centered investigations and prosecutions of perpetrators of atrocities committed in Burma since 2011, by supporting the implementation of the justice and accountability components of UN General Assembly resolution A/RES/78/219 with respect to the situation of human rights of Rohingya and other ethnic and/or religious minority groups in Myanmar. A successful project will result in the advancement of victim-survivor-centered investigations and prosecutions of perpetrators of atrocities committed in Burma since 2011.

NHTSA is responsible for reducing vehicle-related fatalities and injuries on our nations highways. Over the years, NHTSA has developed a significant body of evidence supporting the effectiveness of certain traffic safety laws, regulations and policies that can reduce traffic crashes. State legislatures effectuate traffic safety policy through enacting laws that aim to reduce fatalities and injuries due to motor vehicle crashes. In addition to other salient information, State legislators benefit from learning about the implementation and effectiveness of other jurisdictions traffic safety laws to provide a foundation to make informed decisions on effective traffic safety policy. Therefore, the tracking of laws, sharing of information regarding effectiveness and outcomes, legislative staff, and transportation stakeholders is critical to the publics safety. Since it is vital that information regarding effective traffic safety laws and legislative trends be available to the groups mentioned above, NHTSA seeks to engage an organization that serves legislators and staffs of the nation's 50 states and territories (hereafter, the term State will include the District of Columbia, Puerto Rico and U.S. territories) to educate members of state legislatures to canvass and review the various state laws addressing traffic safety issues that can form the basis for new or improvements to existing state traffic safety laws. In addition, NHTSA seeks to identify best practices for members of state legislatures to communicate and cooperate both at the intrastate and interstate level to develop effective traffic safety laws. The information gathered, research conducted, and materials created would also be available to stakeholders and the public to benefit a larger understanding of the ways laws at the State level influence overall safety.

The PMGP was started in 1970 to support research in the field of fundamental measurement or the determination of fundamental constants, enabling the faculties at universities and colleges and laboratory researchers to conduct significant research in this area. By funding the research projects of eligible applicants through this program, NIST supports advances in fundamental measurement, the determination of fundamental constants, and fosters extramural collaboration with NIST scientists.